Barclays
OLMA icon

Barclays’s Olema Pharmaceuticals OLMA Stock Holding History

Barclays’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
13,998
-119,127
-89% -$2.65M ﹤0.01% 3665
2025
Q4 		$3.33M Buy
133,125
+28,501
+27% +$507K ﹤0.01% 2543
2025
Q3 		$1.02M Sell
104,624
-51,216
-33% -$308K ﹤0.01% 3353
2025
Q2 		$664K Buy
155,840
+2,736
+2% +$12.2K ﹤0.01% 3597
2025
Q1 		$576K Buy
153,104
+38,225
+33% +$192K ﹤0.01% 3442
2024
Q4 		$670K Buy
114,879
+19,964
+21% +$199K ﹤0.01% 3648
2024
Q3 		$1.13M Buy
94,915
+48,614
+105% +$621K ﹤0.01% 3279
2024
Q2 		$501K Buy
46,301
+3,491
+8% +$37.9K ﹤0.01% 3047
2024
Q1 		$485K Sell
42,810
-586
-1% -$7.56K ﹤0.01% 3615
2023
Q4 		$609K Buy
43,396
+38,739
+832% +$521K ﹤0.01% 3758
2023
Q3 		$57.5K Sell
4,657
-695
-13% -$7.08K ﹤0.01% 3810
2023
Q2 		$48.3K Buy
5,352
+730
+16% +$4.41K ﹤0.01% 3852
2023
Q1 		$16K Buy
4,622
+714
+18% +$2.91K ﹤0.01% 4691
2022
Q4 		$9.57K Sell
3,908
-1,669
-30% -$4.87K ﹤0.01% 4936
2022
Q3 		$16K Buy
5,577
+1,749
+46% +$7.42K ﹤0.01% 4139
2022
Q2 		$16K Sell
3,828
-4,212
-52% -$13.4K ﹤0.01% 4486
2022
Q1 		$34K Buy
+8,040
New +$44.3K ﹤0.01% 4259

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Barclays's OLMA Position: Q1 2026 in Review

Barclays reduced its Olema Pharmaceuticals (OLMA) stake by 89% in Q1 2026, selling an estimated $2.65M and leaving 13,998 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #3665.

Barclays first reported a position in OLMA in Q1 2022 and has held it in 17 quarters since. The position peaked at $3.33M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Barclays held 13,998 shares of Olema Pharmaceuticals worth $209K as of Q1 2026.
  • Barclays sold 119,127 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.65M.
  • Olema Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3665 holding.
  • Barclays first reported a position in Olema Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Olema Pharmaceuticals position peaked at $3.33M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.